enrolment temporariliy stopped for budget considerations
ESME OC
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database : Evolution of the Therapeutic Care in Ovarian Cancer Across the French Comprehensive Cancer Centers From 2011
Sponsor study identifier
observational
13,331
1 country
20
Study Start
April 1, 2017
Actual (reported)Primary Completion
December 31, 2025
Actual (reported)Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This database compiles data from existing data available from patient's electronic medical records (EMR).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 1, 2017
Actual (reported)June 27, 2017
Actual (reported)September 7, 2017
Actual (reported)December 31, 2025
Actual (reported)December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Describe the evolution of therapeutic care in ovarian cancer across the French comprehensive cancer centers
Patient characteristics, tumor characteristics and treatment patterns
baseline
Describe the impact of therapeutic strategies on survival criteria
From date of diagnosis or first treatment until the date of date of death from any cause. Follow up until 2022.
Describe the impact of therapeutic strategies on survival criteria
From date of diagnosis or first treatment until the date of first documented progression or date of death from any cause. Follow up until 2022.
Any female treated for ovarian cancer in a French comprehensive cancer centers
All consecutive females treated for an ovarian cancer in a French Comprehensive Cancer Center over the selection period.
Institut de Cancérologie de l'Ouest - Paul Papin
Angers, 49933, France
Institut Bergonié
Bordeaux, 33076, France
Centre François Baclesse
Caen, 14076, France
Centre Jean Perrin
Clermont-Ferrand, 63011, France
Centre Georges-François Leclerc
Dijon, 21079, France
Centre Oscar Lambret
Lille, 59020, France
Centre Léon Bérard
Lyon, 69373, France
Romeo, C, P Meeus, M Rodrigues, E Leblanc, A Floquet, P Pautier, F Marchal, et al. " EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment ". In ePoster, A513.3-A513. BMJ Publishing Group Ltd, 2019. https://doi.org/10.1136/ijgc-2019-ESGO.1013.
De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecol Oncol. 2021 Oct;163(1):64-71. doi: 10.1016/j.ygyno.2021.07.019. Epub 2021 Jul 19.
Rodrigues M, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Provensal Gross M, Leblac E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Courtinard C, Gladieff L. Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France. ESMO Congress, September 16-21, 2021 [ePoster 746P] DOI:https://doi.org/10.1016/j.annonc.2021.08.1188
13,331 participants (actual enrollment reported by the registry).
First Submitted
June 27, 2017
First Posted
September 7, 2017
Study Start
April 1, 2017
Actual (reported)Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
Contact the study team to confirm eligibility.
Institut Paoli-Calmettes
Marseille, 13273, France
Institut régional du Cancer Montpellier / Val d'Aurelle
Montpellier, 34298, France
Institut de Cancérologie de Lorraine
Nancy, 54511, France
Institut de cancérologie de l'Ouest - René Gauducheau
Nantes, 44805, France
Centre Antoine Lacassagne
Nice, 06189, France
Institut Curie
Paris, 75005, France
Institut Jean Godinot
Reims, 51056, France
Centre Eugène Marquis
Rennes, 35042, France
Centre Henri Becquerel
Rouen, 76038, France
Institut Curie - Hôpital René Huguenin
Saint-Cloud, 92210, France
Centre Paul Strauss
Strasbourg, 67065, France
Institut Claudius Regaud
Toulouse, 31059, France
Institut Gustave Roussy
Villejuif, 94805, France
Thomas QD, Boussere A, Classe JM, Pomel C, Costaz H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, Rouge TM, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecol Oncol. 2022 Oct;167(1):11-21. doi: 10.1016/j.ygyno.2022.08.005. Epub 2022 Aug 13.
Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F. Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database. Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M. Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. Int J Gynecol Cancer. 2023 Apr 3;33(4):577-584. doi: 10.1136/ijgc-2022-003993.
Rippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, Gladieff L, Pautier P, Frenel JS, Costaz H, Lebreton C, Pomel C, Colombo PE, Marchal F, Guillemet C, de la Motte Rouge T, Eberst L, Bosquet L, Deluche E, Sabatier R. PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. Oncologist. 2025 May 8;30(5):oyaf075. doi: 10.1093/oncolo/oyaf075.
Chator C, Chevrier M, Frenel JS, Guyon F, Sabatier R, Pomel C, Rouge TM, Pautier P, Gladieff L, Follana P, Colombo PE, Petit T, Guillemet C, Marchal F, Narducci F, Fumet JD, Rodrigues M, Bosquet L, Rouzier R, Ray-Coquard I. Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database. Gynecol Oncol. 2025 Oct;201:17-25. doi: 10.1016/j.ygyno.2025.08.004. Epub 2025 Aug 7.
Papazyan T, Martin E, Pautier P, Guerin-Charbonnel C, Rowinski E, Lecuru F, Joly F, De La Motte Rouge T, Guillemet C, Costaz H, Sabatier R, Barranger E, Colombo PE, Marchal F, Pomel C, Savoye AM, Bosquet L, Ray-Coquard I, Gladieff L, Loaec C, Frenel JS. Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database. Int J Gynecol Cancer. 2026 Feb;36(2):102804. doi: 10.1016/j.ijgc.2025.102804. Epub 2025 Nov 14.
Mokarram Dorri N, Foulhioux L, Zemmour C, Thomas QD, Costaz H, Narducci F, Petit T, Loaec C, Laas E, Gyuon F, Cherifi F, Savoye AM, Ferraioli D, Rossi L, De la Motte Rouge T, Marchal F, Gosset M, Pomel C, Martin AL, Lambaudie E. Metastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort. Clin Surg Oncol. 2025; 4(4)
Le Bars S, Guerin-Charbonnel C, Martin E, Thomas QD, Costaz H, Pomel C, Marchal F, Narducci F, Gouy S, Laas E, Rossi L, Lambaudie E, Rouzier R, Petit T, Gladieff L, De La Motte Rouge T, Bosquet L, Colombo PE, Classe JM, Loaec C. Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database. Eur J Surg Oncol. 2026 Jun;52(6):111768. doi: 10.1016/j.ejso.2026.111768. Epub 2026 Mar 25.
Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, Rouge TM, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M. Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas. Int J Gynecol Cancer. 2025 May;35(5):101866. doi: 10.1136/ijgc-2024-005815. Epub 2025 Apr 19.
Primary Completion
December 31, 2025
Actual (reported)Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 27, 2026
Record last verified: 2026-04
In accordance with ethical and legal requirements related to the ESME Data Warehouse, individual data from the ESME databases cannot be made available outside Unicancer secured servers.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: